| Product Name | Osilodrostat (LCI699) |
|---|---|
| CAS | 928134-65-0 |
| Formula | C13H10FN3 |
| MW | 227.24 |
| Appearance | White to yellow pwder |
| Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 1 mg | 3-5days | ¥350.00 | Visible after login | |
| 5 mg | 3-5days | ¥660.00 | Visible after login | |
| 10 mg | 3-5days | ¥1150.00 | Visible after login |
| Product Name | Osilodrostat (LCI699) |
|---|---|
| CAS | 928134-65-0 |
| Formula | C13H10FN3 |
| MW | 227.24 |
| Appearance | White to yellow pwder |
| Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Osilodrostat, also known as LCI699, is a potent inhibitor of 11β-hydroxylase, the enzyme which catalyzes the final step of cortisol synthesis. LCI699 may thus be a potential new treatment for all forms of Cushing's syndrome. Current evidence indicates that the novel aldosterone inhibitor LCI699 is an effective and well-tolerated antihypertensive agent that lowers plasma aldosterone concentration and produces a mild ACTH-stimulated cortisol response suppressive effect.